All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Bright days are ahead for China’s biopharmaceutical sector, which is getting a reset from the efforts to tackle COVID-19 through innovation and advancements. “I'm consciously optimistic about the fact that cross-border deals will continue,” Stella Xu, managing director, Quan Capital, from Shanghai, China said during a panel discussion at the Chinabio Partnering Forum.